1 day Ago By Defense World Staff
Bank of New York Mellon Corp boosted its position in Nuvation Bio Inc. ( NYSE:NUVB – Free Report ) by 33.6% in the 2nd quarter, according to its most recent filing with the SEC.
The fund owned 626,905 shares of the company’s stock after purchasing an additional 157,511 shares during the period. Bank of New York Mellon Corp owned about 0.25% of Nuvation Bio worth $1,831,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of NUVB. Vanguard Group Inc. boosted its holdings in shares of Nuvation Bio by 3.
0% during the 1st quarter. Vanguard Group Inc. now owns 7,534,148 shares of the company’s stock valued at $27,424,000 after acquiring an additional 219,533 shares in the last quarter.
Price T Rowe Associates Inc. MD increased its position in shares of Nuvation Bio by 551.8% during the first quarter.
Price T Rowe Associates Inc. MD now owns 1,354,632 shares of the company’s stock worth $4,932,000 after acquiring an additional 1,146,794 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Nuvation Bio by 81.
9% in the 1st quarter. Acadian Asset Management LLC now owns 1,174,464 shares of the company’s stock worth $4,273,000 after acquiring an additional 528,660 shares during the last quarter. Octagon Capital Advisors LP bought a new position in Nuvation Bio in the 4th quarter valued at about $1,510,000.
Finally, Jacobs Levy Equity Management Inc. boosted its stake in Nuvation Bio by 254.1% during the 1st quarter.
Jacobs Levy Equity Management Inc. now owns 748,793 shares of the company’s stock valued at $2,726,000 after purchasing an additional 537,314 shares during the last quarter. Institutional investors own 61.
67% of the company’s stock. Nuvation Bio Stock Performance NUVB stock opened at $3.07 on Wednesday.
The firm has a 50 day moving average of $3.13 and a 200-day moving average of $3.00.
The firm has a market capitalization of $765.17 million, a P/E ratio of -9.90 and a beta of 1.
38. Nuvation Bio Inc. has a 12 month low of $0.
95 and a 12 month high of $4.16. Insiders Place Their Bets In other Nuvation Bio news, Director Xiangmin Cui bought 87,715 shares of Nuvation Bio stock in a transaction dated Thursday, June 20th.
The shares were purchased at an average cost of $2.99 per share, with a total value of $262,267.85.
Following the completion of the purchase, the director now owns 1,762,951 shares of the company’s stock, valued at $5,271,223.49. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website .
Insiders own 36.09% of the company’s stock. Analysts Set New Price Targets NUVB has been the subject of several analyst reports.
Wedbush reissued an “outperform” rating and issued a $5.00 price objective on shares of Nuvation Bio in a research note on Wednesday, September 11th. Royal Bank of Canada reissued an “outperform” rating and set a $5.
00 target price on shares of Nuvation Bio in a research report on Tuesday, August 6th. Finally, HC Wainwright cut their price target on shares of Nuvation Bio from $8.00 to $7.
00 and set a “buy” rating on the stock in a report on Monday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $6.
40. Check Out Our Latest Analysis on NUVB About Nuvation Bio ( Free Report ) Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Articles Five stocks we like better than Nuvation Bio Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours? Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? How is Compound Interest Calculated? Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Health Care Stocks Explained: Why You Might Want to Invest Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding NUVB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvation Bio Inc.
( NYSE:NUVB – Free Report ). Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter .
.
